Schroder Investment Management Group Novavax Inc Transaction History

Schroder Investment Management Group

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$36.28 - $75.29 $1.95 Million - $4.05 Million	-53,836 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$69.73 - $142.9 $140,227 - $287,371	2,011 Added 3.88%	53,836 $4.02 Million
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $2.07 Million - $3.35 Million	-15,363 Reduced 22.87%	51,825 $7.42 Million
Q3 2021 Nov 12, 2021	SELL	$177.8 - $270.58 $10.5 Million - $16 Million	-59,191 Reduced 46.84%	67,188 $13.9 Million
Q2 2021 Aug 13, 2021	BUY	$121.0 - $257.67 $1.46 Million - $3.12 Million	12,093 Added 10.58%	126,379 $26.8 Million
Q1 2021 May 17, 2021	SELL	$112.98 - $319.93 $5.87 Million - $16.6 Million	-51,955 Reduced 31.25%	114,286 $20.7 Million
Q4 2020 Feb 16, 2021	BUY	$78.74 - $139.5 $1.12 Million - $1.98 Million	14,162 Added 9.31%	166,241 $18.5 Million
Q3 2020 Nov 13, 2020	BUY	$79.44 - $178.51 $8.79 Million - $19.7 Million	110,591 Added 266.56%	152,079 $15.8 Million
Q2 2020 Aug 13, 2020	BUY	$13.86 - $83.61 $575,023 - $3.47 Million	41,488 New	41,488 $3.46 Million

291

95.2M

7.02M

9.49M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $612M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.